CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The NANEMIAR project develops a novel mRNA-based therapy targeting congenital anemia, aiming to improve treatment efficacy and safety. It also advances knowledge in non-viral delivery systems for broader applications in cell and gene therapy.
Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and low toxicity.
Compared to DNA-based gene therapy, mRNA has significant advantages including higher intrinsic safety (non-integrating), lower cost of development, and less stringent regulatory requirements for clinical approval.
In the NANEMIAR project, we take advantage of these benefits to kill 2 birds with 1 stone: first, we develop a first-of-its-kind na…
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Murcia
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Netherlands, NIJMEGEN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
